Teva Pharmaceutical Industries Limited (TEVA)
| Previous Close | 13.98 |
| Open | 13.92 |
| Bid | 14.11 x 3000 |
| Ask | 14.12 x 2200 |
| Day's Range | 13.81 - 14.13 |
| 52 Week Range | 7.09 - 14.47 |
| Volume | |
| Avg. Volume | 9,279,165 |
| Market Cap | 15.953B |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings Date | May 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 27, 2017 |
| 1y Target Est | 15.50 |
Insider MonkeyCorcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript May 1, 2024 Corcept Therapeutics Incorporated beats earnings expectations. Reported EPS is $0.2503, expectations were $0.21. Corcept Therapeutics Incorporated isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank […]
Business WireTeva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
TEL AVIV, Israel, May 02, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2023 Healthy Future Report, sharing its actions to promote healthy people, a healthy planet and a healthy business. The report unveils new targets to achieve net zero emissions across Teva’s operations and value chain by 2045 and 100% renewable electricity across all Teva sites by 2035, as well as to reach 200% more total beneficiaries of health system strengthening and capacity building
- Thomson Reuters StreetEvents
Q1 2024 Corcept Therapeutics Inc Earnings Call
Q1 2024 Corcept Therapeutics Inc Earnings Call
